Table 3.
Clinical implications of PCA3 plus TMPRSS2-ERG assays (adapted from [56]).
| Model | Prostate Biopsies Avoided (n = 443) n (%) | Prostate Cancers Missed (n = 196) n (%) | Prostate Cancers Gleason ≥ 7 Missed (n = 115) n (%) |
|---|---|---|---|
| PCA3 score ≥ 25 | 166 (37) | 37 (19) | 20 (17) |
| PCA3 score ≥ 35 | 211 (48) | 62 (32) | 36 (31) |
| TMPRSS2-ERG ≥ 10 | 382 (86) | 150 (77) | 75 (65) |
| PCA3-25 plus TMPRSS2-ERG | 153 (35) | 26 (13) | 11 (10) |
| PCA3-35 plus TMPRSS2-ERG | 195 (44) | 48 (24) | 24 (21) |
TMPRSS2-ERG: v-ets erythroblastosis virus E26 oncogene homolog; PCA3 score: [copies PCA3 mRNA]/[copies PSA mRNA] × 1000; TMPRSS2-ERG positive: ≥ 10 copies TMPRSS2-ERG mRNA; PCA3-25 plus TMPRSS2-ERG: TMPRSS2-ERG positive and/or PCA3 ≥ 25; PCA3-35 plus TMPRSS2-ERG: TMPRSS2-ERG positive and/or PCA3 ≥ 35.